

List of Supplemental Material

1. Supplemental Table 1. Amplification and sequencing primers used for the identification of the c.3G>C *CARD9* (Caspase Recruitment Domain Family Member 9) mutation in Patient 2.
2. Supplemental Figure 1. Biallelic *CARD9* (Caspase Recruitment Domain Family Member 9) mutations in the patients with extrapulmonary aspergillosis.
3. Supplemental Figure 2. *CARD9* (Caspase Recruitment Domain Family Member 9) deficiency does not impair the ability of neutrophils to prevent *Aspergillus* conidial germination into hyphae.
4. Supplemental Figure 3. *CARD9* (Caspase Recruitment Domain Family Member 9) deficiency does not impair neutrophil-mediated oxidative cytotoxicity against *Aspergillus fumigatus*.
5. Supplemental Figure 4. The c.883C>T *CARD9* (Caspase Recruitment Domain Family Member 9) loss-of-function mutation is associated with impaired neutrophil accumulation in the infected tissue.
6. Supplemental Figure 5. *CARD9* (Caspase Recruitment Domain Family Member 9) deficiency does not impair neutrophil chemotaxis.


SUPPLEMENTAL TABLES

Supplemental Table 1. Amplification and sequencing primers used for the identification of the c.3G>C *CARD9* (Caspase Recruitment Domain Family Member 9) mutation in Patient 2.


Amplification primers	Primer sequence	Annealing temperature	Product size
x1-2amp 662F	CTGAGATGCTGGCGAGGGCGAGGGTGTTCG	68.5	2677
x1-2amp 3338R	CGGGCCGGCTCCTTGCCCTGTGACCTTCTTGTA		
x3-7amp 2806F	GCCCCAGGCCCAACCCCAACCAC	67.5	2303
x3-7amp 5108R	GCCGGAGGATTGCTTGAGGCCAGTAGTTTGA		
x8-10amp 6616F	ACCGGGGTGCAGGCTTGGGAGGAGAC	67.8	1704
x8-10amp 8319R	TCGCCCCATCTTCTAGCTTCATGCACCTGGTCGTT		
x11-13amp 9249F	CTGGCATCTGGCGCCTCCTGGAGCAATGA	68.5	1741
x11-13amp 10989R	CGCGCAGCGCAGTCCGCAGCATCC		
Sequencing primers	Primer sequence		
x1seq 931F	GGGGCCTCCTGGGCTGGGCGAATCAGAA		
x1seq 1322R	AAATGAACACATCTCCGCCAGGGGCCGTGAAAG		
x2seq 2410F	TGGGGGATCCAGCGTGGGGATGGGACATG		
x3seq 3507R	CGTGTTCCCCGGTGGCCCAGCTCCATCA		
x4seq 3492F	GCCACCGGGGAACACGGCACCATCTGACAC		
x5-6seq 3999F	AGCCTCATGAAGGCCGAGGACGACTGCAAGGTG		
x5-6seq 4309R	AGCGCCTGCCGCCAGTCCTCCTCCAGTACCT		
x7seq 5108R	GCCGGAGGATTGCTTGAGGCCAGTAGTTTGAG		
x8seq 7305R	AGGCCCCCTCCATGCCCAACAACCTGCTAGG		
x9seq 7384F	CTGCCCTCACAGCCCACCCACCCATTTTCTATGA		
x10seq 7969R	CATTGCGGCACGGGCTGCCTGTGCTGAA		
x11-13seq 9388F	CGGGGAGGGGTGGGGCAGCCGTGCTATA		
x11-13seq 10735R	GAGCGGGAATGCGGGTCACCCGTGCTGTTATTTA		

SUPPLEMENTAL FIGURES


A Sequencing



B RFLP (Patient 1)



C




Supplemental Figure 1. Biallelic *CARD9* (Caspase Recruitment Domain Family


Member 9) mutations in the patients with extrapulmonary aspergillosis. (A) Sequencing

chromatogram of a healthy WT/WT individual (upper panel) and of Patient 1 (lower panel)

showing homozygous c.883C>T *CARD9* mutation (rs121918338). (B) The *CARD9* stop codon polymorphism (rs121918338) of Patient 1 was confirmed by restriction-fragment length polymorphism (RFLP) analysis. (M) 100 bp marker, (1) undigested PCR product of a healthy WT/WT individual, (2) digested PCR product of a healthy WT/WT individual, (3) undigested PCR product of Patient 1, (4) digested PCR product of Patient 1. Digestion with BfaI (restriction site: CTAG). (C) Sequencing chromatogram of Patient 2 (middle panel) and two healthy WT/WT individuals (upper and lower panels) showing homozygous c.3G>C *CARD9* mutation.




Supplemental Figure 2. CARD9 (Caspase Recruitment Domain Family Member 9) deficiency does not impair the ability of neutrophils to prevent *Aspergillus* conidial germination into hyphae. Representative images of *Aspergillus* hyphal germination 20 hours after *ex vivo* co-incubation of conidia with control neutrophils (middle panel), neutrophils from Patient 1 (right panel) or no exposure to neutrophils (left panel).




Supplemental Figure 3. CARD9 (Caspase Recruitment Domain Family Member 9) deficiency does not impair neutrophil-mediated oxidative cytotoxicity against

Aspergillus fumigatus. (A) Neutrophils from Patient 1 do not exhibit impaired release of hydrogen peroxide toward various fungal and non-fungal stimuli *ex vivo*, determined by the Amplex Red method (n = 3 healthy donors; n = 1 experiment with Patient 1 cells). STZ, serum-treated zymosan; PMA, phorbol-12-myristate-13-acetate; PAF, platelet-activating factor; fMLP, formyl-Met-Leu-Phe. (B-I) Neutrophils from healthy donors (B and C) and Patient 2 (D and E) induce similar degrees of GFP fluorescence in the *A. fumigatus* B-5233/GFP strain upon oxidative stress (white arrows). GFP-fluorescence is induced in the *A. fumigatus* B-5233/GFP strain by 375 μ M hydrogen peroxide (positive control; F and G) but not by R25 media alone (negative control; H and I). (B, D, F, and H), light microscopy. (C, E, G and I), fluorescence microscopy. All quantitative data represent mean \pm SEM.



Supplemental Figure 4. The c.883C>T *CARD9* (Caspase Recruitment Domain Family Member 9) loss-of-function mutation is associated with impaired neutrophil accumulation in the infected tissue. Periodic acid–Schiff (PAS) stain of the mesenteric lymph node biopsy of Patient 1 shows necrotic tissue with invasion by branching hyphae, consistent with *Aspergillus* species. No neutrophil infiltration is seen. Magnification, 400× (upper left and lower right panels); 200× (upper right and lower left panels).



Supplemental Figure 5. CARD9 (Caspase Recruitment Domain Family Member 9)

deficiency does not impair neutrophil chemotaxis. Neutrophils from Patient 1 and another CARD9-deficient patient with the c.883C>T (p.Q295X) mutation do not exhibit impaired chemotaxis toward complement component C5a (10^{-8} M), IL-8 (10^{-8} M) or platelet-activating factor (PAF; 10^{-7} M) *ex vivo*. Two healthy donors were used as controls on two independent experiments.